Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022 ...Middle East

HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC), in...

Hence then, the article about akeso announces oral presentation of ivonescimab pd 1 vegf bi specific in first line treatment of es sclc on aclc 2022 was published today ( Monday 31/10/2022 - 03:56 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022 )

Also on site :

• My Wife Doesn’t Know I Watched Her Cheat On Me. My Reaction Might Shock Us Both.
• The Good Ship Murder Christmas special cast: Meet the characters
• No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl